Siliq (brodalumab)

pCPA File Number: 21053

Negotiation Status:

Concluded with an LOI

Indication(s):

Psoriasis, moderate to severe plaque

Sponsor/Manufacturer:

Valeant Canada

CDA-AMC Project Number:

SR0547-000

pCPA Engagement Letter Issued:

2018-10-05

Negotiation Process Concluded:

2018-12-14